CREABILIS THERAPEUTICS AND BIONUCLEON ENTER COLLABORATION AGREEMENT. - Colleretto Giacosa, Bioindustry Park Canavese, Italy - CREABILIS therapeutics SpA and Bionucleon Srl, today announced a collaboration agreement to co-develop new aptamer-based compounds against targets involved in inflammatory and autoimmune diseases. S. Traversa, CREABILIS therapeutics’ Chief Scientific Officer, said: “This collaboration represents an important additional strengthening of the ongoing projects of CREABILIS in the research of new therapeutical agents against targets involved in inflammation.” R. Sapio, Administrator and co-founder of Bionucleon, commented: “We are very pleased to collaborate with CREABILIS therapeutics.
International Press Release Publishing for free in 15 languages across 22 countries
Press Releases
Google-Suche:
 

Send this page to somebody

Fill in the email address of your friend to send an email with the address.
Address info
(Required)
The e-mail address to send this link to.
(Required)
Your email address.
A comment about this link.
 
 
Pressreleases by authors
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z